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Abstract 
Background: Chagas disease is regarded as a risk for travelers to continental Latin America. 
However this risk has not been quantified before. Objective: To determine the risk of T. cruzi 
infection among returning travelers visiting friends and relatives (VFRs) to endemic areas, to 
describe the demographic and travel characteristics, and to identify risk factors for acquiring T. 
cruzi infection. Design: prospective descriptive study. Methods: All available adults with 
laboratory proof of being free of Chagas disease before travel at University Hospital Vall 
d’Hebron in Barcelona, Spain from 2012 to 2015 were recruited for standardized questionnaire 
and measurement of T. cruzi antibodies in serum. Results: 60 participants were included in the 
study. All were immigrants from Central or South America living in Spain, who traveled to visit 
friends and relatives. 45/60 (75%) were female, the median age was 38.5 years old. The median 
duration of travel was 43.5 days (IQR 30-63.5 days). 35/60 (58%) visited rural areas. Fresh fruit 
juices and sugar cane were consumed by 36/60 (60%) of participants. Housing construction 
material prone to Reduviid bug infestation (adobe, palm tree-thatching, wooden or cane walls) 
were only met by 2/60 (3.3%). 59/60 (98%) of travelers VFR were negative for T. cruzi infection 
after travel to endemic areas, and one case 1/60 (2%) had discordant inconclusive serology. 
Limitations: The number of eligible patients was reduced by the amount of patients unreachable 
by telephone (313/633, 49.3%), and many were unable to participate due to strict working shifts, 
which may have selected for more females in our study.  Conclusions: Among 60 travelers VFR 
to endemic areas we found no cases of Chagas disease. Travelers were proven to be free of T. 
cruzi infection prior to travel. This study provides the basis for future studies that aim to evaluate 
the risk of acquiring Chagas disease during travel to endemic areas to provide evidence for 
improvement of clinical recommendations and public health screening efforts.  
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Introduction 
 Concerns that international travel to Latin America may pose risk to acquire Chagas 
disease (CD) have been proposed and are part of health travel recommendations. Trypanosoma 
cruzi infection is endemic in 21 countries in Central and South America. In Europe and other 
non-endemic areas, CD is an emerging infection and much awareness has been raised recently 
due to its public health implications. However, the risk of acquiring CD in a single trip to 
endemic areas has not been quantified. Chagas disease has been reported among travelers before, 
but whether the infection was acquired prior or during to travel has not been established. The 
chronic indeterminate phase of CD can last for decades, therefore we think it is necessary to rule 
out prior infection in travelers of Latin American origin in order to quantify the risk of travel. 
This knowledge would represent the scientific evidence to support both pre-travel counseling and 
screening efforts. It may be possible that the risk of acquiring Chagas disease after travel is 
minimal, even among travelers visiting friends and relatives (VFR) who exhibit riskier 
behaviors. We analyze data from all available patients documented to be free of Trypanosoma 
cruzi infection prior to travel to endemic areas at University Hospital Vall d’Hebron in 
Barcelona, Spain from 2012 to 2015 as a pilot study that will serve as a guide for a larger scale 
study. 
 Trypanosoma cruzi is the causal agent of Chagas disease or American trypanosomiasis. It 
is named after Dr. Carlos Chagas, the Brazilian physician who described the parasite, its 
biological cycle, and clinical manifestations in 1909 during the construction of a railroad system 
in Brazil.  T. cruzi is a hemoflagellate protozoan, and its most common mode of transmission is 1
through a bloodsucking vector. Reduviid insects from the genera Triatoma, Panstrongylus, and 
Rhodnius are the vectors most frequently implicated in human infection.  These vectors are 2
widely distributed in the Americas from the southern part of the United States (US) to Chile and 
Argentina. Chagas disease has been present in the Americas as an enzootic disease for thousands 
of years. There is molecular evidence of T. cruzi infection in mummies from pre-Columbian era 
in the Andes region 9000 years before present (BP) and evidence of megacolon due to CD in a 
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mummy dated 1150 BP from what is now Texas, US.   The interaction between parasite and 3
human hosts has evolved over time and has determined the epidemiological trends in endemic 
areas, but globalization is now determining epidemiology worldwide. The role that travelers to 
endemic areas play in the epidemiology of non-endemic areas is not fully understood. 
The parasite and its life cycle 
 The life cycle of Trypanosoma cruzi begins when the vector becomes infected by having 
a blood meal from an infected mammal or human. The protozoa multiply in the insect’s midgut 
as epimastigotes, and develop in the insect’s hindgut as trypomastigotes which is the infective 
form. During the following blood meal, usually at night, infective trypomastigotes are eliminated 
in its feces. The infective parasites gain access to the mammal or human through skin breaks, 
mucous membranes, or conjunctivae, which completes its transmission cycle. Once inside its 
new host, T. cruzi is able to multiply as intracellular amastigotes similar to Leishmania. Inside 
the host cell, amastigotes differentiate into trypomastigotes which are then released into 
circulation once the cell ruptures. Thus, Trypanosoma cruzi spreads hematogenously to distant 
sites to begin new life cycles.  4
  
Transmission and clinical manifestations 
 In addition to vectorial-borne, the other modes of transmission have gained relevance in a 
globalized world: blood transfusion, organ donation, congenital, and food-borne infection. 
Vectorial and oral transmission of T. cruzi are exclusive to the Americas. Infection related to 
blood products, donation of organs, and mother to child occur worldwide and have come to 
highlight the importance of screening at-risk populations. The socioeconomic burden of disease 
has motivated prevention initiatives in non endemic areas like Europe, Australia, Japan, and the 
United States. This review puts emphasis on vectorial and oral transmission due to their 
pertinence to travelers to continental Latin America.  
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 Vectorial transmission of Trypanosoma cruzi is by far the most common mode of 
transmission of Chagas disease. It follows a sylvatic and a domestic cycle in which humans are 
incidental hosts, affected by their interactions with the environment and animals. When land is 
opened for human activities - may it be construction of railways, farming, or urbanization in 
enzootic areas - the vector adapts to living in human dwellings and feeding on domestic animals. 
Certain housing conditions, have been identified as risk factors because they provide crevices 
and nooks for Reduviid insects to thrive. Describing such conditions as “poor dwellings” may be 
an oversimplification. An entomologic survey in a periurban area of Arequipa, Perú found that 
52% (194/374) of houses were infested with triatomines, of those 19.3% were infected with T. 
cruzi. Guinea pig pens (OR 1.69) and rabbit enclosures (OR 1.52) were identified as a risk 
factors for triatomine infestation. Adobe or stacked brick increased the likelihood of triatomine 
infestation (OR 2.52). Fully stuccoed walls was identified as a protective factor for both human 
dwellings and animal enclosures.  The presence of hens indoors was identified as a risk factor for 5
Triatoma infestans in human dwellings by a study in rural communities in Santiago del Estero, 
Argentina.  Palm trees are also a preferred habitat for triatomine bugs, and palm leaves are often 6
used for roof thatching. A study found that 27% of palm trees near human dwellings were 
infested by Rhodnius ecuadoriensis, in 3 different climatic areas of Ecuador.  The density of the 7
vector is patchy throughout the Americas, some areas like “el Gran Chaco”, a vast plain that 
includes parts of Argentina, Bolivia and Paraguay, have a much higher vector population and 
prevalence of Chagas disease in humans.  
 Briefly, the natural history of disease acquired by vectorial transmission includes an 
“acute phase” with a self-limited febrile illness. Physical signs that point to the site of entry of T. 
cruzi are the Romaña’s sign (conjunctivae), and the “chagoma” (skin), which are present only in 
few patients. The very young and the immunocompromised hosts may present with severe forms 
of disease like meningoencephalitis and myocarditis. In most cases, the acute phase may pass 
largely unnoticed and resolves spontaneously in 4 to 8 weeks. It is followed by the “chronic 
indeterminate phase” where the patient remains asymptomatic for decades, but with low-level 
intermittent parasitemia and detectable antibodies. This phase is relevant to public health because 
 10
transmission can still occur despite lack of symptoms. A variable percentage, 30-40% of infected 
patients go on to develop the mega-syndromes of the “chronic phase”. Cardiac abnormalities 
occur in ~30%, with  biventricular dilatation, congestive heart failure, arrhythmias, are the most 
frequent. The gastrointestinal (GI) system is affected in ~10% with megaesophagus, 
dolichocolon, and megacolon. The largest patient-series from a non-endemic country (n=1274) 
was reported at our Institution.  A lower proportion of cardiac and GI compromise was found 8
compared to patient-series from endemic areas, likely due to the younger age of migrants, and 
use of routine diagnostic studies for infected patients. 
 Oral transmission of Trypanosoma cruzi is responsible for outbreaks of massive 
parasitic infection leading to severe disease with high death rates. Unlike other food-borne 
infections, acute Chagas disease from oral transmission causes acute myocarditis with electrical 
conduction abnormalities and varying degrees of heart failure. Fever, facial edema, gingivitis, 
cervical lymphadenopathies, hepatomegaly, and skin rash have been described. Interestingly, 
acute Chagas from oral transmission does not always manifest with gastrointestinal complaints 
like diarrhea, and if present, is not a prominent symptom. The incubation time is 5 days and 
mortality is more common among young patients. Massive parasitemia is demonstrated by large 
numbers of circulating trypomastigotes of T. cruzi in peripheral blood smear as reported by 
several authors.   Outbreaks of acute Chagas disease linked to foods and beverages have been 9 10
described with increasing frequency in the Americas. They occur in areas not typically endemic 
due to long distance commerce of food.  The first outbreak (n=17) was reported in 1965 in 11
Brazil and was presumed to be linked to vegetables contaminated with feces of marsupials. Since 
then, cases and outbreaks have been reported in Argentina, Brazil, Colombia, and Ecuador. The 
largest documented outbreak occurred in an urban school in  Caracas, Venezuela in 2007. It 
affected 103 people of 1000 exposed to guava juice, of those infected 77 were students, 26 
school employees, and 1 child died.  Other reported food vehicles of T. cruzi infection are sugar 12
cane juice, açaí juice, palm wine, and wild game. In summary, oral transmission of Chagas 
disease can occur by accidental ingestion of the Triatomine insect, ingestion of Triatomine’s 
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feces, direct consumption of infected wild game, foods contaminated by feces or urine of 
marsupials, or human breast milk.   13
What is known about Chagas disease among travelers 
 Perception of risk of acquiring Chagas disease during travel to endemic areas is based on 
case reports of returning travelers with acute CD, and cases diagnosed on migrants of Latin 
American origin living in non-endemic countries. Risk assessment and quantification has not 
been fully established, thus current recommendations are empirical. The Yellow Book from the 
CDC (Center for Disease Control and Prevention of the US) is one of the preferred references on 
international travel for health professionals. Its current recommendation for travelers to Mexico, 
Central and South America focuses on general measures to avoid insect bites and food-borne 
disease. It states that “the risk to travelers is extremely low, but they could be at risk if staying in 
poor-quality housing or from consuming contaminated food or beverages in endemic areas.”  14
 A thorough search of the literature on Chagas disease in returning travelers to Latin 
America yields two types of publications: isolated case reports, and descriptive data from Travel 
Medicine networks. One of the few examples, reports a case of acute Chagas disease in a 53 year 
old female traveler to Puerto Viejo, Costa Rica and diagnosed upon return to the US. This patient 
sought medical attention because of unilateral eye swelling (Romaña’s sign) and high fever. A 
detailed evaluation found trypomastigotes of T. cruzi in peripheral blood smear, and cardiac 
abnormalities (diastolic left ventricular dysfunction, dilated left atrium, small pericardial 
effusion, etc) without other symptom that fatigue.  This case is notable because travel was short-15
term (3 weeks) and that particular region is not associated with a high incidence of CD. 
Presumably, not every case of acute CD in ill returning travelers merits publishing.  
 Regarding consolidated data from Travel Medicine networks, one of the most recent 
reports comes from the European Travel Network. Among 7408 returning travelers evaluated at 
16 EuroTravNet sites across Europe in 2010, 60 cases of chronic Chagas disease were found.  16
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They defined two types of travelers: “travelers with long-term exposure abroad” included recent 
immigrants (evaluated for screening of infectious diseases as they enter the country) and long 
term expatriates (missionaries, volunteers, aid workers, researchers, and people staying abroad 
for business). “Short-term travelers” included: tourists, business travelers, and non-recent 
migrants or their descendants visiting friends and relatives (VFRs) in their countries, 
missionaries, volunteer workers, aid workers and researchers, students, military personnel on 
missions, and medical tourism. They found 58 cases of chronic CD among travelers with long-
term exposure, which represent 9% of 639 recent immigrants seen in 2010. Among travelers with 
short-term exposure, 2 cases of chronic CD were found, which represent <1% of 942 VFRs in 
2010. 58/60 cases were from Bolivia, 1/60 from Ecuador, and 1/60 from Paraguay. Cases came 
mostly from the site in Madrid. 
 A report from the GeoSentinel network on morbidity in travelers visiting Mexico and 
Central America evaluated 4779 ill travelers from December 1996 to February 2010. These 
population consisted of short-term travelers, mostly tourists with median duration of travel 17 
days (interquartile range 8-43 days).  Only 1 case of acute Chagas disease was diagnosed in a 17
26 year old female from Canada who traveled to Mexico for tourism. It was unknown wether she 
received pre-travel advise from a medical professional. A review of the GeoSentinel surveillance 
network on illness in travelers VFR from 1997 to 2004 found no cases of CD.  This report 18
included 502 travelers VFR whose destination was Latin America including the Caribbean 
region, which is not an endemic area.  
Chagas disease in Spain and Europe 
 The current epidemiology of Chagas disease in Europe is determined by screening at 
blood banks, screening programs for the prevention of congenital disease, screening for organ 
donors and recipients, active surveillance of migrants of Latin American origin, and passive 
notification of cases from healthcare centers. The first cases of CD were reported in the 1980s, 
and the increasing number of cases has raised awareness of the importance of screening at-risk 
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population for the prevention of transmission. A recent meta-analysis from studies prior to 2004 
on the prevalence of Chagas disease among Latin American migrants living in European 
countries found a pooled prevalence of 4.2%. The main contribution of this study was to 
compare these numbers with the estimated prevalence of CD in the Americas according to PAHO 
2006 data. Migrants from Bolivia had the highest prevalence 18.1% whereas PAHO reports 
6.75%, followed by Paraguay with 5.5% whereas PAHO reports 2.54%, and Nicaragua with 
4.6% whereas PAHO reports 1.14.  19
 With the initial migratory flows from Latin America to Europe in the 1990’s appeared the 
first cases of patients with Chagas disease diagnosed in European countries. Spain is the 
European country with the largest population of migrants from South American origin. However 
many changes in the migratory trends have occurred in past years. Unfortunately, not all 
measures for the prevention of transmission of CD are implemented across Europe, as is the case 
for prevention of congenital disease. It has already been recommended that up-to-date 
information is needed for adequate health-policy making. Given its public health implications, 
cases of Chagas disease need to be prevented, detected and treated.   20
Chagas disease in the Americas 
 American trypanosomiasis or Chagas disease is a “neglected tropical disease”  endemic 
to 21 countries in the Americas: Argentina, Belize, the Bolivarian Republic of Venezuela, Brazil, 
Chile, Colombia, Costa Rica, Ecuador, El Salvador, French Guyana, Guatemala, Guyana, 
Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, the Plurinational State of Bolivia, 
Suriname, and Uruguay. WHO estimates that 6 to 7 million people worldwide are infected, most 
of them in Latin America, and most people who suffer it are unaware.  The estimated number of 21
people with T. cruzi infection in the Americas was 20 million in 1981.  The latest WHO 22
epidemiological update on Chagas disease in Latin America estimates 5.8 million. Bolivia had 
the highest incidence due to vectorial transmission, followed by Mexico, Colombia, Peru, 
Ecuador, Guatemala, Argentina, El Salvador, Honduras, and Venezuela. The estimated 
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prevalence of infection per 100 habitants due to vectorial transmission was highest in Bolivia, 
followed by Argentina and Paraguay (all 3 are part of the Gran Chaco region), followed by 
Ecuador, El Salvador, and Guatemala.    23
 This great reduction in cases was achieved by multiple factors including spraying with 
residual insecticides. Examples of vector-control programs in Latin America are the Amazon 
(AMCHA), the Andean (IPA), the Central American (IPCA), and the Southern Cone 
(INCOSUR) Initiatives. Other factors include improvement of socioeconomic  metrics like better 
housing conditions, home hygiene, blood donor screening, education and communication. This 
latest WHO epi-report used data from 2010 and did not include new cases due to oral 
transmission. This is particularly relevant for the countries in the Amazon basin and humid 
Andean valleys: Bolivia, Brazil, Colombia, Ecuador, French Guyana, Guyana, Peru, Suriname, 
and Venezuela (grouped as the Amazon Initiative AMCHA) which may have a large burden of 
disease secondary to oral transmission. 
 The risk of transmission by blood transfusion in Latin America is very low because of 
screening programs in most blood banks. Mexico was the country with lowest level of screening 
coverage in 2005, but improved its efforts and reached 92% coverage in 2012.  It is difficult to 24
know certainly how many blood banks are not screening adequately since blood banks do not 
respond to a centralized institution in many countries across Latin America. 
Objectives 
 The main objectives of this study are 1) to determine the frequency of Trypanosoma cruzi 
infection among returning travelers to endemic areas, 2) to describe the demographic and travel 
characteristics, and 3) to identify possible risk factors for acquiring T. cruzi infection and no T. 
cruzi infection.  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Methods 
Study design  
 This is a prospective observational study. It is the first report or pilot study of a multi-
center version to be conducted in other centers across Barcelona and Spain. This study is written 
in accordance with the STROBE reporting guidelines for observational studies.  25
Setting 
 This study recruited adult patients with a negative Trypanosoma cruzi serology test from 
a master list provided by the Microbiology Department at University Hospital Vall d’Hebron and 
Drassanes in Barcelona, Spain from January 2012 to December 2015. Serology had been 
originally requested as part of routine blood bank protocol; clinical workup of findings 
compatible with Chagas disease; prior to chemotherapy, biologicals, transplantation of organs as 
per protocol; or as screening of migrants of Latin American origin at the Tropical Medicine/
International Health Clinic. University Hospital Vall d’Hebron is the largest tertiary care center 
in Barcelona. Patients were recruited in the study from March to May 2017.  
Participants 
 Eligible patients were all adults who had traveled to Central or South America after their 
latest negative T. cruzi serology test. Travel history was elicited by telephone conversation after a 
brief description of our research. Contact telephone numbers were obtained from the electronic 
medical record (EMR) at our institution. Possible outcomes of telephone calls were categorized 
into: “Yes travel”, “No travel”; and “Untraceable”. “Yes travel” patients were invited to 
participate in our study and an appointment was scheduled at the Travel Medicine/International 
Health Clinic, usually within the next 15 days. Reminders via text message were sent to assure 
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attendance. All participants provided a written informed consent, a standardized questionnaire, 
and a blood sample for Trypanosoma cruzi serology. 
 Exclusion criteria were assessed upon review of the medical notes on the EMR for each 
patient. They included: previous discordant T. cruzi serology, negative serology after successfully 
treatment for Chagas disease, and deceased patients. Discordant results were found when the 
latest serological test was negative, but prior tests were positive. This study is approved by the 
Ethics Committee for Clinical Research at University Hospital Vall d’Hebron. 
Variables 
 The outcome variable for this study is the presence of T. cruzi antibodies from a blood 
sample provided by participants. Our institution performs two serological techniques for 
Trypanosoma cruzi antibody detection simultaneously as recommended by the World Health 
Organization (WHO) for the diagnosis of Chagas disease .  The use of T. cruzi serology testing 26
is indicated in “the chronic indeterminate phase” of CD which is occurs after 8 weeks (56 days) 
from infection. Other diagnostic tools should be used for the “acute phase” which can last 
4-8weeks from infection. Possible results are: positive to both antibodies which is diagnostic of 
T. cruzi infection, negative to both antibodies which rules out T. cruzi infection, or discordant 
serology when one antibody is positive and the other is negative. 
 A standardized questionnaire was designed to explore demographic characteristics, travel 
features, and possible behaviors and exposures associated with T. cruzi infection during travel. 
For statistical analysis we included the following quantitative variables: age, duration of travel. 
The following qualitative variables were included: sex, travel destination, reason for travel, rural 
areas, peridomestic farm animals, dogs/cats in or around the house, illness during travel, fever 
during travel. Risk factors of T. cruzi infection were Reduviid bug-bite, blood transfusion, 
consumption of either fresh fruit juices or sugar cane (gruped as beverages for analysis), and 
overnight stay at a house built of adobe or palm tree roofs or walls of cane or wood (grouped 
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together as house construction materials for analysis). The variable “reason for travel” was 
categorized into tourism, business, research or education, missionary or volunteer, and VFR, 
according to publications from GeoSentinel.  For diagnostic accuracy of the outcome variable, 27
the period of time between travel and study participation was calculated for each participant. 
Please see Appendix 1 for a model of the standardized questionnaire. 
  
Data sources / Measurements 
 Efforts to encourage patients to come to clinic included reminder phone calls the day 
prior scheduled appointment; and text messages with date, time, and place of the appointment. 
The standardized questionnaire was filled out by an attending physician at the Tropical Medicine 
Clinic. Demographic data and date of previous T. cruzi serology test were available from the 
EMR. The rest of variables were elicited from the patient as questions during anamnesis, and 
recorded by the physician in a data collection sheet unique for each participant.  
 Blood samples from study participants were analyzed at the main Microbiology 
Laboratory at U.H. Vall d’Hebron. Laboratory personnel were not aware of this study, hence 
samples were analyzed as any other sample would be. Our institution uses two different 
serological methods performed in parallel in accordance to WHO recommendations. One method 
is an enzyme-linked immunosorbent assay (ELISA) with native (whole cell lysate) antigen for 
the detection of human antibodies to T. cruzi (ORTHO® T. cruzi ELISA Test System, Johnson & 
Johnson, High Wycombe, United Kingdom). Performance of this test was measured in different 
populations. The observed sensitivity of this test in high risk populations is 98.9% with a 95% 
exact confidence interval of 94.2-100%. The observed specificity in a high risk population study 
was 99% as reported by the manufacturer’s package insert.  The other method is an ELISA with 28
recombinant antigen (Bioelisa Chagas, Biokit, Lliçà d’Amunt, Spain) for the detection of total 
antibodies to T. cruzi. The package insert reports a sensitivity of 100% and specificity 97.4-100% 
in different studies.  As of February 2015, our Institution uses an ELISA with recombinant 29
antigen from another manufacturer (Bioelisa Chagas, Vircell, Spain) with similar sensitivity and 
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specificity.  Results are expressed as the index between the absorbance of the test serum and the 
threshold value. Interpretation of results was negative with an index <0.9, equivocal if 0.9-1.1, 
and positive is >1.1. The results of T. cruzi serology tests were available within 2-3 days. 
Bias 
 Performance bias when applying the standardized questionnaire to participants was 
avoided because it was applied prior to taking the blood sample to check for T. cruzi antibodies. 
Therefore, interviewer were unaware of the outcome variable at this point. The same is 
applicable to the telephone calls. To avoid bias in variability of the data collection, only 4 
physicians applied the standardized questionnaire, and only 1 investigator performed the 
telephone calls.  
Study size 
 This is a pilot study. The sample size was a convenience sample, determined by all 
available eligible patients between 20212 and 2015 and the number of patients that participated 
by showing up in Tropical Medicine Clinic during the study period March to May 2017.  
 For the on-going multi center study, a sample size was calculated a priori.  With a  95% 
confidence interval (CI), a population size of 2500, an expected proportion to have T. cruzi 
infection after travel to endemic areas of 3%, a desired precision for the CI of +1.5%, and an 
estimated replacement rate of 40%, the sample size of 632 was calculated. The calculator for this 
estimation was the “Sample size and power calculator GRANMO” from the Municipal Institute 
of Medical Research, Barcelona, Spain.  30
Quantitative variables 
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 The date of travel and the date of study participation were known. A new variable was 
created to reflect the time lapsed between the exposure (travel to Latin America) and the date of 
new T. cruzi serology test. This was done to reflect the chronicity of infection and the suitability 
of the diagnostic method. Periods greater than 8 weeks (56 days) would be considered at as 
“chronic indeterminate phase” for participants with the outcome variable. The variable “Duration 
of travel” was measured in days, and was further categorized into <15 days, 16-30 days, 31-60 
days, 61-90 days, 91-180 days, and >181 days. This was to reflect a possible effect between 
duration of exposure and infection with T. cruzi. 
Statistical methods 
 Demographic and travel characteristics were analyzed using descriptive statistics. Linear 
regression between T cruzi-positive and T cruzi-negative to identify significant differences in 
demographic and travel characteristics. Excel was used for tabulation and descriptive analysis 
and DeduceR (R 3.3.1 GUI 1.68 Mavericks build) was used for linear regression model.  
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Results 
 Of the 633 patients with baseline negative T. cruzi serology assessed for eligibility, 
140/633 (22.2%) did not travel, 313/633 (49.3%) were untraceable by telephone, and 58/633 
(9.2%) met exclusion criteria. 122/633 (19.3%) patients were eligible for study participation 
because they did travel to Central or South America. Of those, 60 patients kept their 
appointments and were included in the study and analysis. Patients were untraceable for 6 
reasons: 159 patients could not be reached by telephone despite 3 attempts; 86 patients had 
telephone numbers on record that no longer exist; 26 patients had a wrong telephone number on 
record; 7 patients had restricted in-coming calls; 20 patients did not have a medical record 
number in the EMR, and 15 patients had returned to their home country. Of the eligible patients, 
the main reasons for non-participation were the patient lived in a city different than Barcelona 
(3/122), inability to take time off work (56/122), and unwillingness to participate (3/122). 
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 Regarding demographic characteristics, 45/60 (75%) were female and 15/60 (25%) were 
male patients. The youngest participant was 17 years old (yo) and the eldest was 78 yo. The 
mean age was 41 yo and the Standard Deviation was 11.36 years. The median age was 38.5 yo, 
the 25th percentile was 34 yo, and the 75th percentile was 47.5 yo. Please see Table 1 for 
Demographic and Travel characteristics of the study population. 
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 The country of birth and the country of travel destination were the same in all but 2 
participants, 58/60 (96.7%). One case was born in Bolivia and visited friends and relatives in 
Argentina, the other was born in Colombia and visited Peru. The median duration of travel was 
43.5 days (IQR 30-63.5 days). 90% of our study participants traveled between 2 weeks and 3 
months. When asked about insect bites during travel 30/60 (50%) reported affirmatively, and 
while only 42/60 (70%) recognize the Reduviid-bug, none of the patients 0/60 (0%) reported 
being bitten by the Reduviid-bug. Given the exploratory nature of this study, the patients were 
interviewed with open questions like exposure to peridomestic farm animals during travel. The 
description of which farm animals they were exposed to was missing in 12/60 (20%). 
 Regarding risk factors directly associated with T. cruzi infection, please see Table 2. 
Patients that reported consumption of fresh fruit juices during travel were 42/60 (70%), and 
23/60 (38%) reported sugar cane consumption. Those who consumed both “Beverages” 
implicated with T. cruzi infection were 36/60 (60%) of participants. Regarding housing 
conditions during travel, 11/60 (18%) patients stayed at a house built of adobe; 1/60 (2%)  stayed 
at a house with palm tree roof; 3/60 (5%) stayed at a house with wooden walls; and 2/60 (3%) 
stayed at a house with cane walls. Zero participants received a blood transfusion during travel, 
and none reported being bitten by the Reduviid bug, colloquially known as “vinchuca”. 
  
 Regarding the outcome variable, a negative T. cruzi serology test was obtained in 59/60 
(98%) cases, and a discordant result in 1/60 (2%). None of the study participants had positive T. 
cruzi serology test. 
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Discussion 
Key results 
 Current Travel Medicine recommendations include Chagas disease as a risk for travelers 
to Central and South America. However no previous studies have tried to answer this question, 
thus risk for acquiring Chagas diseases during travel to endemic areas remains unknown. It is 
well described that travelers visiting friends and relatives are at higher risk for infections than 
tourists due to more risky exposures, less protection, and longer stays.  Among 60 adults who 31
traveled to endemic areas to visit friends and relatives and were free of T. cruzi infection prior to 
travel, we found no cases of T. cruzi infection and found 1 patient with discordant serology.  
 A 78 year old female participant in this study had a discordant serology for T. cruzi. She 
was born in Buenos Aires, Argentina and lives in Spain for 17 years. Past medical history 
includes hypertension, obesity, cardiovascular accident, and non-ischemic dilated 
cardiomyopathy with ejection fraction 35% diagnosed in 2015. In January 2015, antibodies for T. 
cruzi were requested as part of diagnostic workup and results were negative. She was eligible for 
this study as she traveled to her home city in December 2015 for 40 days. Upon study 
participation in May 2017, she did not meet any risk factors associated with Chagas disease in 
the standardized questionnaire. T. cruzi serology test showed: positive for T. cruzi anti-
recombinant antibody (index 1.64), and negative T. cruzi anti-native antibody (index 0.01). As 
per protocol, serology test was repeated in a new serum sample, and a second discordant result 
was obtained: positive T. cruzi anti-recombinant antibody (index 1.21), and negative T. cruzi 
anti-native antibody (index 0.01). T. cruzi PCR in blood was negative. These results make 
diagnosis inconclusive. Western blotting like the TESA-Blot (Biomérieux, RJ, Brazil) was 
evaluated as a confirmatory diagnostic tool in patients with inconclusive and discordant serology 
at our institution and helped establish the diagnosis of CD in half of them.    Unfortunately, the 32
TESA-blot is not commercially available in Europe, and this patient will be followed up in clinic 
with repeat serology in 4-6 months. 
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 This is the first study to evaluate the risk of acquiring Chagas disease from travel to 
continental Latin America. We exclusively enrolled patients documented to be free of T. cruzi 
infection prior to travel. We think this is a crucial precaution in order to avoid detecting patients 
who were infected but not diagnosed prior to travel. Previous publications have reported cases of 
Chagas disease among travelers without prior documentation of status of T. cruzi infection. 
EuroTravNet reported 60 cases of CD among travelers and migrants in 2010.16 The majority of 
cases, 58 out of 60, were recent immigrants tested as part of screening of infectious diseases 
upon entry to Spain. The other 2 cases were non-recent migrants traveling to visit family and 
friends in Latin America. It would be incorrect to assume that CD was acquired during their 
latest travel to Latin America. These cases were basically patients in the chronic indeterminate 
phase of infection who were diagnosed during the study period. This phase can last for a lifetime 
in most patients, and they will remain asymptomatic, therefore it is crucial to determine the 
travelers’ serological status prior to travel.  
 Travelers VFRs in this study were migrants of Latin American origin living in Spain for 
several years, middle aged (median 38.5 yo), female predominance (75%), who traveled to their 
home countries to visit friends and relatives. The median duration of travel was 43.5 days (IQR 
30-63.5 days), which is much longer than the duration of travel of the ill returning tourist 
(median 17 days, IQR 8-43).17 Other studies on illness in travelers VFSs have found a male 
predominance, mean age was similar at 38.9, and trip duration >30 days when compared to 
tourists.31 
 Exposure to well described risk factors was assessed with the standardized questionnaire. 
Consumption of fresh fruit juices and sugar cane is very popular in Latin America as was true for 
our population too. Guava, açaí juice and sucking on sugar cane have been implicated in 
outbreaks of food-borne Chagas disease.10, 11, 12, 13 Fresh fruits and vegetables can be 
contaminated with the vector itself or its feces and be inadvertently ingested. With regards to the 
quality of housing conditions, only 12/60 (20%) of participants stayed at a house built of adobe, 
or palm tree-thatching, or cane walls. However, the majority (58%) reported visiting rural areas 
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and exposure to farm animals like chicken, guinea pigs, ducks, cows, pigs, goats, and others. 
This may be explained by better socioeconomic conditions in their home countries reflected in 
the improvement of building materials. Efforts to control de vectors have been successfully 
implemented in Latin America since the 1990s, with significant reduction of vectorial 
transmission in many countries and eradication in others.23 Although 70% said they were able to 
recognize the “vinchuca” or Reduviid bug, 100% denied being bitten by it. Reduviid bugs bite at 
night when the human host is unaware, so this information just shows that the insect is familiar 
to most of our population.  
Limitations 
 Telephone contact was necessary to assess for eligibility, which probably explains the 
large number of untraceable patients (313/633, 49.3%) we found. Presumably these patients do 
not keep the same telephone number for a long period of time. Of those who were reachable by 
telephone, half of eligible patients (62/122, 51%) were unable to come to the study site. Reasons 
for this include inability to get time off from work, several jobs that immigrants fill are shift 
which offer  little or no flexibility. Female participants tend to work taking care of children or the 
elderly, and this gives them more time flexibility than their male counterparts. Also, there was no 
immediate benefit of participating in this study, so participants may have wanted to “save” work 
leaves for more “important” needs. Male immigrants’ work schedule overlapped with the 
working hours of our study site, which may have introduced a selection bias to represent more 
females than males. Although the pre-test probability is low to begin with, we included all 
available data between January 2012 and February 2015 in this study. 
Interpretation 
 Exposures during travel to endemic areas that were identified as risk factors for T. cruzi 
infection were consumption of fresh fruit juices and sugar cane, and housing materials prone to 
Reduviid bug infestation. Participants who met both of these risk factors were 10/60 (16.7%), 
 27
those who met either one risk factor were 38/60 (63.3%), and patients who did not meet any risk 
factor for CD were 12/60 (20%). None cases of Trypanosoma cruzi infection were acquired after 
travel to endemic areas. One patient had discordant serology results.  
 This is the first study to evaluate the risk of T. cruzi infection among travelers to Latin 
America taking the precaution to prove that  participants were free of CD disease before travel. 
This study provides the basis for which future studies aiming to evaluate the risk of acquiring 
Chagas disease after travel to Central and South America. This knowledge would represent the 
scientific evidence to support both pre-travel counseling and screening efforts among migrants of 
Latin America living in non-endemic countries. The role that travel to endemic areas play in the 
epidemiology of CD in non-endemic areas is a relevant matter in our present globalized world. 
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Appendix 1 
Data Collection Sheet  - Standardized Questionnaire  
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